INTRODUCTION: Until now, there was no validated and reliable tool to estimate life expectancy among patients with cancer-associated hypercalcemia (CAH). This study aimed to validate a prognostic score previously published. METHODS: We studied a new cohort of 252 patients with CAH. Our prognostic score based on the four poor-prognosis factors (liver metastasis, squamous cell carcinoma, hypoalbuminemia, and calcemia >2.83 mmol) was implemented to this cohort. The accuracy of this score for the prediction of 90-day mortality was estimated with area under the curve of the receiver operator curve (AUC-ROC). RESULTS: Among this validation cohort, patients with score = 0 experienced a median overall survival of 797 days; whereas, patients with score >/=1 (at least one poor-prognosis factor) had median overall survival of 49 days (p < 0.0001). The AUC-ROC for the prediction of 90-day mortality were 0.88 (0.76-0.86) and 0.67 (0.61-0.74) in the development cohort and in the validation cohort, respectively. CONCLUSION: We have validated a reliable bedside prognostic score for CAH.
INTRODUCTION: Until now, there was no validated and reliable tool to estimate life expectancy among patients with cancer-associated hypercalcemia (CAH). This study aimed to validate a prognostic score previously published. METHODS: We studied a new cohort of 252 patients with CAH. Our prognostic score based on the four poor-prognosis factors (liver metastasis, squamous cell carcinoma, hypoalbuminemia, and calcemia >2.83 mmol) was implemented to this cohort. The accuracy of this score for the prediction of 90-day mortality was estimated with area under the curve of the receiver operator curve (AUC-ROC). RESULTS: Among this validation cohort, patients with score = 0 experienced a median overall survival of 797 days; whereas, patients with score >/=1 (at least one poor-prognosis factor) had median overall survival of 49 days (p < 0.0001). The AUC-ROC for the prediction of 90-day mortality were 0.88 (0.76-0.86) and 0.67 (0.61-0.74) in the development cohort and in the validation cohort, respectively. CONCLUSION: We have validated a reliable bedside prognostic score for CAH.
Authors: P Major; A Lortholary; J Hon; E Abdi; G Mills; H D Menssen; F Yunus; R Bell; J Body; E Quebe-Fehling; J Seaman Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: Anis Rassi; Anis Rassi; William C Little; Sérgio S Xavier; Sérgio G Rassi; Alexandre G Rassi; Gustavo G Rassi; Alejandro Hasslocher-Moreno; Andrea S Sousa; Maurício I Scanavacca Journal: N Engl J Med Date: 2006-08-24 Impact factor: 91.245
Authors: Nicolas Penel; Sylvain Dewas; Philippe Doutrelant; Stéphanie Clisant; Yazdan Yazdanpanah; Antoine Adenis Journal: Support Care Cancer Date: 2007-08-21 Impact factor: 3.603
Authors: S R Nussbaum; J Younger; C J Vandepol; R F Gagel; M A Zubler; R Chapman; I C Henderson; L E Mallette Journal: Am J Med Date: 1993-09 Impact factor: 4.965
Authors: James C Cripe; Tommy R Buchanan; Leping Wan; Andrea R Hagemann; Carolyn K McCourt; L Stewart Massad; Katherine C Fuh; David G Mutch; Mathew A Powell; Premal H Thaker; Lindsay M Kuroki Journal: Gynecol Oncol Rep Date: 2019-01-26